Clinical Trial Update: Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study comparing 2.5 mg saxagliptin and 500 mg metformin tablets, including a fixed-dose combination tablet, in healthy participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glucophage (metformin)
• Onglyza (Saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2011-10-21